跳至主要内容
临床试验/TCTR20201121001
TCTR20201121001尚未招募未知

Site of intravitreal injection and pain assessments from a randomized clinical trial

Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University0 个研究点目标入组 80 人开始时间: 2020年11月21日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 Years 至 0 N/A (No limit)(—)
性别
All

入选标准

  • Age > or = 20 years
  • Diagnosed with neovascular (wet-type) age-related macular degeneration or diabetic macular edema or central retinal vein occlusion
  • Confirmed with optical coherence tomography (OCT) or fundus fluorescein angiography (FFA) or both
  • Need for intravitreal bevacizumab injection as the treatment for the first time in out-patient department or retina clinic, Department of Ophthalmology, KCMH

排除标准

  • Patient with any of the following conditions:
  • History of intravitreal injection
  • Contraindicated in intravitreal injection
  • Abnormality or scar on sclera, episclera or conjunctiva
  • Ophthalmic disease requiring ophthalmic drop other than lubrication
  • Intraocular pressure > or = 22 mmHg
  • History of scleritis or episcleritis
  • History of cranial nerve V abnormality
  • History of intraocular surgery
  • History of neovascular glaucoma
  • Limitation of extraocular muscle interfering the injection

研究者

发起方
Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University

相似试验